Akero Therapeutics Initiates Study of Efruxifermin in NASH/MASH Patients
Akero Therapeutics is conducting a multi-center, randomized, double-blind, placebo-controlled study of efruxifermin in patients with non-cirrhotic NASH/MASH and fibrosis.
Company
Pharmaceutical intelligence for Akero Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.